Naproxen
Brand names: Naprosyn, Napratec, Naproxen EC
Naproxen is a non-selective non-steroidal anti-inflammatory drug widely used in rheumatology for the symptomatic relief of pain and inflammation in conditions such as rheumatoid arthritis, osteoarthritis, gout and ankylosing spondylitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It non-selectively inhibits cyclo-oxygenase enzymes COX-1 and COX-2, reducing prostaglandin synthesis to produce anti-inflammatory, analgesic and antipyretic effects.
Prescribing in practice
- Use the lowest effective dose for the shortest duration because of dose-related risks of serious gastrointestinal bleeding and ulceration, particularly in older patients and those on anticoagulants, with gastroprotection considered where appropriate.
- It can cause fluid retention, raised blood pressure and renal impairment, so use caution in heart failure, hypertension and chronic kidney disease.
- Avoid in active peptic ulceration and severe heart failure, and use cautiously with other nephrotoxic or anticoagulant drugs.
Monitoring
Monitor blood pressure, renal function and for gastrointestinal symptoms during longer-term use, especially in those with comorbidity.
Counselling the patient
- Take with or after food and report black stools, vomiting blood or severe indigestion.
- Avoid combining with other anti-inflammatory painkillers including over-the-counter ones.
- Stay hydrated and report swelling or reduced urine output.
Evidence & guidelines
Naproxen is a first-line NSAID in UK rheumatology practice and is noted to carry a relatively favourable cardiovascular risk profile among NSAIDs in NICE guidance.
Reference: NICE NG100 RA; NICE NG219 Gout; MHRA NSAIDs prescribing guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022